Designing and Development of a Tandem Bivalent Nanobody against VEGF₁₆₅.

ABSTRACT:

Background

Inhibition of angiogenesis using monoclonal antibodies is an effective strategy in cancer therapy. However, they could not penetrate sufficiently into solid tumors. Antibody fragments have solved this issue. However, they suffer from short in vivo half-life. In the current study, a tandem bivalent strategy was used to enhance the pharmacokinetic parameters of an anti-VEGF165 nanobody.

Methods

Homology modeling and MD simulation were used to check the stability of protein. The cDNA was cloned into pHEN6C vector and the expression was investigated in WK6 Escherichia coli (E. coli) cells by SDS-PAGE and western blot. After purification, the size distribution of tandem bivalent nanobody was investigated by dynamic light scattering. Moreover, in vitro<

SUBMITTER: Khodabakhsh F 

PROVIDER: S-EPMC8112138 | biostudies-literature | 2021 Apr-Jun

REPOSITORIES: biostudies-literature